3 juli 2022

IVERMECTIN BEATS OUT 9 OTHER MEDS FOR TREATING OMICRON

”Researchers used computational analyses to evaluate the performance of 10 medications against the Omicron variant, finding ivermectin outperformed all of them, including nirmatrelvir (Paxlovid), a new drug from Pfizer that has cost taxpayers $5.29 billion and costs $529 per course of treatment.

Story at-a-glance: 

Researchers used computational analyses to evaluate the performance of 10 medications against the Omicron variant, finding that ivermectin outperformed all of them, including nirmatrelvir (Paxlovid) a new drug from Pfizer that has cost taxpayers $5.29 billion and costs $529 per course of treatment.

Ivermectin lowers the viral load by inhibiting replication, reduces infection by 86% when used preventively, speeds recovery, protects against organ damage, lowers the risk of hospitalization and death and costs between $48 and $95 for a course of treatment depending on your location.

Early treatment lowers your risk of long COVID, which includes physical and mental health conditions. According to cardiologist Dr. Peter McCullough, 50% of those sick enough to be hospitalized have symptoms of long COVID.

Africa has a lower number of cases, severity of disease, hospitalizations and deaths than other areas of the world, which may be due to using prophylactic medications for endemic infections that have successfully treated COVID.

At nearly no other time in history has there been this level of fear generated across the world as experienced thus far in 2020 and 2021. The depth and breadth of the strategies used to stoke those fears have been overwhelming.

Emergency use authorizations for drugs that have not proven to be effective in trials, public mask mandates for which there is no scientific evidence and the suppression and censorship of health information has boosted public fear over a viral illness with a survival rate of over 99%.”

Continue to read the article here:

Lämna ett svar

Din e-postadress kommer inte publiceras.

Genom att använda sidan, samtycker du till att all information som finns eller presenteras på denna webbplats inte är avsedd för någon form av diagnos, medicinsk behandling eller rekommendation, utan att den endast presenteras för utbildningsändamål av intresse för personligt bruk för läsaren, som själv tar fullt ansvar för dess användning. För ytterligare information och om sidans användande av så kallade kakor, GDPR, se även sidans  Integritetspolicy.